HTA Database - Search Results

Sort by Relevance

Search Results [1526 Hits] Selected Records [0 Hits] [Clear]

Year	Source	Title
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: cervical cancer screening in Québec - recommendations for implementing the human papillomavirus detection test (HPV test) as the primary screening test]
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Breast cancer risk assessment tools
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Structured screening questionnaires for alcohol misuse/alcohol use disorders
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: evaluation of the relevance of newborn screening for severe combined immunodeficiency SCID]
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Regulation and financing of prenatal screening and diagnostic examinations for fetal anomalies in selected European countries
2022	NIHR Health Services and Delivery Research programme	Components of interventions to reduce restrictive practices with children and young people in institutional settings: the Contrast systematic mapping review
2022	Ontario Health	First-trimester screening program for the risk of pre-eclampsia using a multiple-marker algorithm: a health technology assessment
2022	NIHR Health Technology Assessment programme	Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: Hereditary Cardiovascular diseases NGS Panel - Evaluation report on the repatriation of an analysis carried out outside of the province of Québec]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: update of the optimal usage guide on sexually transmitted and blood borne infections – confirmed Mycoplasma genitalium infection]
2022	Austrian Institute for Health Technology Assessment (AIHTA)	[Risk-based breast cancer screening in Austria: a systematic analysis of predictive models to assess individual breast cancer risk, their utility and applicability in a breast cancer screening programme]
2022	Norwegian Institute of Public Health (NIPH)	First trimester-screening for the development of preeclampsia with the use of an algorithm: a health technology assessment
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Search for guidelines on population-based colorectal cancer screening]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Review of age limits in the mammography screening programme]
2022	Andalusian Health Technology Assessment Area (AETSA)	[Clinical effectiveness, safety, and economic assessment of mass screening for hepatitis C. Systematic review]
2022	NIHR Health Technology Assessment programme	Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling
2022	NIHR Health Technology Assessment programme	EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Perinatal and infant mental health care models and pathways
2022	Malaysian Health Technology Assessment (MaHTAS)	Early cancer detection test for lung (EarlyCDT-Lung)
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Adjunctive colposcopy technologies (videocolposcopy) for cervical conditions]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Prenatal cell-free DNA in maternal blood screening to assess chromosomal disorders in single pregnancy]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for argininosuccinic aciduria (ASA)]
2022	Scottish Health Technologies Group (SHTG)	The Psychology Adding Value – Epilepsy Screening (PAVES) and early intervention for children and young people with epilepsy at risk of mental health problems
2022	Health Sciences Institute in Aragon (IACS)	[Digital dermatoscopy]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Digital breast tomosynthesis]
2022	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Screening tools for frailty in users undergoing cardiac surgery requiring a sternotomy]
2022	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Systematic review on diagnosis and care of reactive attachment disorder]
2022	Ontario Health	Genetic testing for familial hypercholesterolemia
2022	The Regional Health Technology Assessment Centre (HTA-centrum)	Progesterone, cerclage, pessary, or acetylsalicylic acid for prevention of preterm birth in singleton and multifetal pregnancies
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Blood values: do older people benefit from regular determination of vitamin B12 and vitamin D levels in the blood?]
2022	Norwegian Institute of Public Health (NIPH)	Zephyr® valves system in the treatment of emphysema: a single technology assessment
2021	NIHR Health Technology Assessment programme	The cystic fibrosis (CF) anti-staphylococcal antibiotic prophylaxis trial (CF START); a randomised registry trial to assess the safety and efficacy of flucloxacillin as a longterm prophylaxis agent for infants with CF
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: noninvasive fetal RhD genotyping using maternal plasma]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: artificial intelligence-assisted diabetic retinopathy tele-screening]
2021	NIHR Health Technology Assessment programme	Universal late pregnancy ultrasound screening to predict adverse outcomes in nulliparous women: a systematic review and cost-effectiveness analysis
2021	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Newborn screening for classic congenital adrenal hyperplasia. Update and assessment of regional programs]
2021	Austrian Institute for Health Technology Assessment (AIHTA)	[Parent-Child-Pass Update 2020/21 – Screenings for mental health, nutrition and social competence]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guidelines and standards: initiating blood work for the purpose of evaluating diagnosed or suspected alcohol use disorder]
2021	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Screening for common mental disorders during pregnancy and for traumatic experiences after delivery]
2021	NIHR Health Technology Assessment programme	Modelling tool to support decision-making in the NHS Health Check programme: workshops, systematic review and co-production with users
2021	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Recommendations for the appropriate use of vitamin D tests and supplements in the general population]
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Palliative care screening tools
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Genetic testing for Lynch syndrome in colorectal cancer and family members]
2021	NIHR Public Health Research (PHR) programme	School-based interventions to prevent anxiety, depression and conduct disorder in children and young people: a systematic review and network meta-analysis
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: relevance of using mpMRI for the diagnostic investigation of prostate cancer - mpMRI and prostate cancer diagnosis]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: relevance of neonatal pulse oximetry screening for critical congenital heart disease]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: mammographic density and breast cancer screening]
2021	Health Information and Quality Authority (HIQA)	Extended interval screening by the Diabetic RetinaScreen Programme in Ireland
2021	Health Information and Quality Authority (HIQA)	Potential impact of different serial testing scenarios using rapid antigen detection tests (RADTs) to detect SARS-CoV-2 in meat processing plant workers
2021	Health Information and Quality Authority (HIQA)	Review of processes in use to inform the expansion of newborn bloodspot screening programmes
2021	Health Information and Quality Authority (HIQA)	Health technology assessment of birth cohort testing for hepatitis C
2021	Health Information and Quality Authority (HIQA)	Rapid antigen testing for screening or surveillance of asymptomatic individuals to limit transmission of SARS-CoV-2
2021	Austrian Institute for Health Technology Assessment (AIHTA)	Stool DNA testing for colorectal cancer (CRC) screening
2021	Health Technology Wales (HTW)	Handheld single lead electrocardiogram devices to detect atrial fibrillation in older adults and those with intermittent episodes
2021	Health Information and Quality Authority (HIQA)	Review of international ethics frameworks used in policy-making in the context of screening
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: efficacy and safety of onasemnogene abeparvovec, nusinersen and risdiplam for the treatment of spinal muscular atrophy]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: assessment of the relevance of newborn screening for spinal muscular atrophy]
2021	Swiss Federal Office of Public Health (FOPH)	Effectiveness and safety of vitamin B12 tests
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: care pathways leading to the diagnostic assessment of neurodevelopmental disorders in children 0-7 years old]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Benefit assessment of medicinal products with new active ingredients according to section 35a SGB V: Blinatumomab (new therapeutic indication: B-precursor acute lymphoblastic leukaemia, relapsed or refractory, Ph+ CD19+)]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ivacaftor/Tezacaftor/Elexacaftor (Exceeding the € 50 Million Limit, Cystic Fibrosis, Combination Treatment with Ivacaftor in Patients 12 Years and Older (Heterozygous for F508del and MF Mutation))]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ivacaftor/Tezacaftor/Elexacaftor (exceeding the € 50 million limit, cystic fibrosis, combination treatment with Ivacaftor in patients 12 years and older (homozygous for F508del mutation))]
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Prevention of tuberculosis reactivation
2021	Basque Office for Health Technology Assessment (OSTEBA)	[Efficacy of high flow oxygen therapy for the treatment of respiratory distress in children]
2021	Adelaide Health Technology Assessment (AHTA)	Guidelines for preparing assessments for the Medical Services Advisory Committee. Version 1.0
2021	Health Technology Wales (HTW)	Transcranial magnetic stimulation for the treatment of depression
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Tafamidis for transthyretin amyloid cardiomyopathy]
2021	Canary Health Service	[Prenatal screening for toxoplasmosis]
2021	Health Sciences Institute in Aragon (IACS)	[Clinical effectiveness of sFlt-1 to PlGF ratio tests for the evaluation of preeclampsia]
2021	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Systematic review about effectiveness of digital pathology as a diagnostic tool for pathology and cytopathology]
2021	Canary Health Service	[Molecular markers for the detection of clinically significant prostate cancer]
2020	NIHR Health Technology Assessment programme	Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT
2020	NIHR Health Technology Assessment programme	Pre-Operative Behavioural Intervention to Reduce Drinking before elective orthopaedic Surgery (Pre-Op BIRDS)
2020	NIHR Health Services and Delivery Research programme	Dementia and cognitive impairment in the older prison population of England and Wales: identifying individual need and developing a skilled, multi-agency workforce to deliver targeted and responsive services
2020	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical Efectiveness of Newborn Screening for Inborn Errors of Metabolism by MS/ MS. Update and pilot study assessment: Maple Syrup Urine Disease; Isovaleric Acidaemia; Homocystinuria]
2020	Basque Office for Health Technology Assessment (OSTEBA)	[Neonatal hearing screening programmes: A systematic review of economic evaluation studies and descriptive analysis of Spanish regional programmes]
2020	NIHR Health Technology Assessment programme	Point-of-care creatinine tests to assess kidney function for outpatients requiring contrast-enhanced CT imaging: systematic reviews and economic evaluation
2020	Norwegian Institute of Public Health (NIPH)	Abdominal aorta aneurysm (AAA) screening of men aged 65
2020	Norwegian Institute of Public Health (NIPH)	Safety, clinical effectiveness, predictive accuracy and cost effectiveness of blood based tests for women with suspected preeclampsia: a health technology assessment
2020	Scottish Health Technologies Group (SHTG)	Second-generation colon capsule endoscopy (CCE-2) for the detection of colorectal polyps – SHTG Recommendation
2020	NIHR Health Services and Delivery Research programme	Understanding and improving experiences of care in hospital for people living with dementia, their carers and staff: three systematic reviews
2020	Health Technology Wales (HTW)	Rapid collaborative review on the diagnostic accuracy of molecular methods that detect the presence of the SARS-COV-2 virus in people with suspected COVID-19
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: tomosynthesis and breast cancer: diagnostic evaluation and other uses]
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Genetic testing in the context of familial hypercholesterolaemia management. Organisational and ethical implications (part 1), and economic aspects (part 2)
2020	Austrian Institute for Health Technology Assessment (AIHTA)	[Lung cancer screening in risk groups]
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Lung cancer screening in risk groups: a review-update of the economic evidence (Part II)
2020	National Committee for Technology Incorporation (CONITEC)	[Newborn screening for congenital toxoplasmosis]
2020	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Comparative results of the different screening strategies used for T21, T18 and T13: adaptation of the EUnetHTA assessment]
2020	European Network for Health Technology Assessment (EUnetHTA)	Lung cancer screening in risk groups
2020	European Network for Health Technology Assessment (EUnetHTA)	Rapid collaborative review on the current role of antibody tests for novel coronavirus SARS-COV-2 in the management of the pandemic
2020	European Network for Health Technology Assessment (EUnetHTA)	Rapid collaborative review on the diagnostic accuracy of molecular methods that detect the presence of SARS-COV-2 virus in people with suspected COVID-19
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: temperature screening for healthcare personnel
2020	Malaysian Health Technology Assessment (MaHTAS)	Programmatic management of latent tuberculosis infection
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Human papilloma virus (HPV) vaccine in patients with HPV lesions or infection]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Digital tomosynthesis for breast cancer]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Virtual colonoscopy for colorectal cancer screening in patients with diverticular disease]
2020	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Clinical effectiveness of pulse oximetry for neonatal screening of critical congenital heart diseases]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Burosumab (reassessment after the deadline: hypophosphataemia)]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Burosumab (new therapeutic indication: X-linked hypophosphataemia, ≥ 18 years)]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Givosiran (acute hepatic porphyria, ≥ 12 years)]